US Stock MarketDetailed Quotes
RSLS ReShape Lifesciences
- 5.9400
- +0.1900+3.30%
Close Nov 29 13:00 ET
- 5.5741
- -0.3659-6.16%
Post 17:02 ET
4.23MMarket Cap-592P/E (TTM)
5.9400High5.6207Low24.56KVolume5.7400Open5.7500Pre Close139.40KTurnover3.64%Turnover RatioLossP/E (Static)712.68KShares34.220052wk High2.85P/B4.01MFloat Cap4.600052wk Low--Dividend TTM674.87KShs Float4647888000.0000Historical High--Div YieldTTM5.55%Amplitude4.6000Historical Low5.6740Avg Price1Lot Size
ReShape Lifesciences Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 6.36%2.29M | -12.82%1.97M | -15.00%1.94M | -22.79%8.68M | -36.27%1.98M | -22.98%2.16M | -22.06%2.25M | -6.27%2.29M | -17.35%11.24M | -1.02%3.11M |
| Operating revenue | 6.36%2.29M | -12.82%1.97M | -15.00%1.94M | -22.79%8.68M | -36.27%1.98M | -22.98%2.16M | -22.06%2.25M | -6.27%2.29M | -17.35%11.24M | -1.02%3.11M |
| Cost of revenue | -1.61%853K | -21.60%831K | -26.72%779K | -29.47%3.13M | -90.73%140K | 24.39%867K | 5.05%1.06M | -13.01%1.06M | -15.50%4.44M | 10.54%1.51M |
| Gross profit | 11.72%1.44M | -5.03%1.13M | -4.82%1.17M | -18.44%5.55M | 15.13%1.84M | -38.70%1.29M | -36.59%1.19M | 0.49%1.22M | -18.52%6.8M | -9.91%1.6M |
| Operating expense | -27.12%3.2M | -38.73%3.19M | -50.77%3.38M | -40.42%20.19M | -45.30%3.74M | -37.02%4.39M | -51.58%5.2M | -26.54%6.86M | -4.78%33.88M | -15.29%6.83M |
| Selling and administrative expenses | -27.23%2.8M | -39.66%2.79M | -54.84%2.89M | -42.98%17.87M | -52.94%3M | -39.76%3.85M | -53.78%4.62M | -25.44%6.4M | -5.63%31.34M | -19.78%6.37M |
| -Selling and marketing expense | -59.85%719K | -69.22%670K | -53.30%1.02M | -46.44%7.55M | -35.19%1.4M | -31.25%1.79M | -53.04%2.18M | -53.52%2.18M | 58.47%14.09M | -20.32%2.16M |
| -General and administrative expense | 1.17%2.08M | -13.33%2.12M | -55.64%1.87M | -40.15%10.32M | -62.02%1.6M | -45.61%2.06M | -54.41%2.45M | 8.43%4.22M | -29.07%17.25M | -19.51%4.21M |
| Research and development costs | -26.38%399K | -31.33%399K | 6.84%484K | -8.75%2.32M | 59.96%739K | -7.03%542K | -22.22%581K | -39.19%453K | 7.09%2.54M | 272.58%462K |
| Operating profit | 43.25%-1.76M | 48.77%-2.05M | 60.75%-2.21M | 45.94%-14.64M | 63.78%-1.9M | 36.30%-3.1M | 54.77%-4.01M | 30.59%-5.63M | 0.57%-27.08M | 16.81%-5.23M |
| Net non-operating interest income expense | 0 | -55.56%4K | 280.00%9K | 123.01%26K | 110.63%17K | -83.87%5K | -35.71%9K | -600.00%-5K | 86.42%-113K | -471.43%-160K |
| Non-operating interest income | --0 | -55.56%4K | ---- | ---- | ---- | -83.87%5K | -35.71%9K | ---- | ---- | ---- |
| Total other finance cost | ---- | ---- | -280.00%-9K | -123.01%-26K | ---- | ---- | ---- | --5K | --113K | ---- |
| Other net income (expense) | 142.96%186K | -8.02%470K | -99.26%22K | 116.89%3.28M | 101.90%211K | 94.38%-433K | 187.20%511K | 10,966.67%2.99M | 45.12%-19.4M | 63.68%-11.13M |
| Gain on sale of security | -77.62%77K | -103.81%-18K | -100.10%-3K | 2,865.96%3.9M | -70.25%97K | 223.30%344K | 331.37%472K | 18,562.50%2.99M | 94.67%-141K | 16,400.00%326K |
| Special income (charges) | --0 | 1,200.00%429K | ---- | 96.14%-744K | --0 | 89.54%-777K | 108.66%33K | ---- | 41.08%-19.27M | 62.61%-11.46M |
| -Less:Impairment of capital assets | --0 | ---- | ---- | -95.85%777K | --0 | -89.54%777K | ---- | ---- | -38.84%18.74M | -63.08%11.32M |
| -Less:Other special charges | ---- | ---429K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Gain on sale of property,plant,equipment | --0 | --0 | ---- | 106.24%33K | --0 | --0 | 108.66%33K | ---- | ---529K | ---146K |
| Other non- operating income (expenses) | --109K | 883.33%59K | 1,150.00%25K | 1,009.09%122K | 5,600.00%114K | ---- | 700.00%6K | -81.82%2K | --11K | --2K |
| Income before tax | 55.40%-1.58M | 54.71%-1.58M | 17.71%-2.18M | 75.67%-11.34M | 89.91%-1.67M | 71.86%-3.53M | 63.02%-3.49M | 67.25%-2.65M | 26.53%-46.59M | 55.30%-16.53M |
| Income tax | 100.00%6K | 275.00%15K | 0.00%14K | 113.68%52K | 155.36%31K | 100.83%3K | -55.56%4K | -53.33%14K | -38.69%-380K | 81.14%-56K |
| Net income | 55.26%-1.58M | 54.34%-1.6M | 17.62%-2.19M | 75.36%-11.39M | 89.69%-1.7M | 71.00%-3.53M | 63.01%-3.49M | 67.20%-2.66M | 26.81%-46.21M | 55.09%-16.47M |
| Net income continuous Operations | 55.26%-1.58M | 54.34%-1.6M | 17.62%-2.19M | 75.36%-11.39M | 89.69%-1.7M | 71.00%-3.53M | 63.01%-3.49M | 67.20%-2.66M | 26.81%-46.21M | 55.09%-16.47M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 55.26%-1.58M | 54.34%-1.6M | 17.62%-2.19M | 75.36%-11.39M | 89.69%-1.7M | 71.00%-3.53M | 63.01%-3.49M | 67.20%-2.66M | 26.81%-46.21M | 55.09%-16.47M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 55.26%-1.58M | 54.34%-1.6M | 17.62%-2.19M | 75.36%-11.39M | 89.69%-1.7M | 71.00%-3.53M | 63.01%-3.49M | 67.20%-2.66M | 26.81%-46.21M | 55.09%-16.47M |
| Basic earnings per share | 94.76%-3.11 | 94.44%-3.48 | 94.23%-5.22 | 98.25%-110.78 | 99.79%-4.1985 | 96.21%-59.36 | 95.58%-62.64 | 92.87%-90.48 | 62.31%-6.32K | 65.86%-2.04K |
| Diluted earnings per share | 94.76%-3.11 | 94.44%-3.48 | 94.23%-5.22 | 98.25%-110.78 | 99.79%-4.1985 | 96.21%-59.36 | 95.58%-62.64 | 92.87%-90.48 | 62.31%-6.32K | 65.86%-2.04K |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data